Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cullinan Oncology Inc. (CGEM) PT Raised to $30 at BTIG
April 17, 2024 5:08 AM EDTBTIG analyst Kaveri Pohlman raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $30.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PT to $30 from $20 after Cullinan's recent corporate update since CLN-978's drug... More
